Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.39 |
| ▸ | BRAF | P15056 | 17/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413362 | 0.91 | GAA (0.43) | POLBGAABTK | |
| SCHEMBL4423656 | 0.85 | BTK (0.39) | POLBGAABTK | |
| SCHEMBL4414898 | 0.83 | BTK (0.40) | BRAFPOLBGAABTK | |
| SCHEMBL4415706 | 0.82 | HPGD (0.44) | POLBGAABTK | |
| SCHEMBL4414867 | 0.82 | GBA1 (0.36) | POLBBTK | |
| SCHEMBL4418158 | 0.80 | SMN1; SMN2 (0.39) | POLBGAABTK | |
| SCHEMBL4421392 | 0.80 | HPGD (0.41) | BRAFPOLBGAA | |
| SCHEMBL4552356 | 0.79 | BRAF (0.48) | RAF1BRAFPOLB | |
| SCHEMBL4417986 | 0.79 | USP30 (0.49) | RAF1BRAF | |
| SCHEMBL4414890 | 0.79 | ALDH1A1 (0.41) | POLBGAABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | claimed |
| EP-1680124-A4 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2009-05-13 | — | — | EP | claimed |
| JP-2007508374-A | — | — | 2007-04-05 | — | — | JP | claimed |
| EP-1680124-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | Pfizer Products Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | PFIZER INC. | 2005-05-05 | — | — | US | claimed |
| WO-2005037216-A2 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1680124-B1 | BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS | PFIZER PROD INC (US) | 2017-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096375-A1 | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | SLC6A5, SLC1A5, SLC6A3 | RAF1 2136/4885BRAF 3436/4885POLB 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.